JBIO
Jade Biosciences, Inc.
$15.34
-4.60%
$757.2M
No data for this timeframe.
Vol
Market Cap$757.2M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (94%)
Inst. Holders50 funds
Inst. Value$351.9M
Inst. Activity8 buys / 12 sells
Reddit Sentiment50° Neutral
SEC Reports9
Press Releases5
Recent Activity
Jun 10, 2026
short_volume
Short Volume: JBIO — 62.5% short (0.4M / 0.7M)
Short: 413,618 | Exempt: 0 | TRF Vol: 661,824 | Short Ratio: 62.5% | Off-exchange volume (dark pool
Jun 9, 2026
Insider
Fairmount Funds Management LLC was granted 34,843 shares
Director
Jun 9, 2026
Insider
Lavelle Erin was granted 34,843 shares
Director
Jun 9, 2026
Insider
DOBMEIER ERIC was granted 34,843 shares
Director
Jun 5, 2026
Press
Jade Biosciences closed a public offering of 11.5M shares at $15.00/share, raising $172.5M in gross proceeds. The procee
Impact 6/10
Jun 5, 2026
SEC
Jade Biosciences reported interim Phase 1 data for JADE101, an anti-APRIL antibody for IgAN. The data showed ~70% mean I
8-K — Impact 7/10
Jun 4, 2026
SEC
Jade Biosciences priced a public offering of 10,000,000 shares of common stock at $15.00 per share, with an underwriter
8-K — Impact 6/10
Jun 4, 2026
SEC
Jade Biosciences priced a $150M underwritten public offering of 10M shares at $15.00/share (14.7% discount to the $17.59
424B5 — Impact 7/10
Price Targets
$49.00
+219.4% upside
Strong Buy
Current $15.34
Low $40.00
Median $45.00
High $74.00
7 analysts
$40.00
$74.00
Analyst Ratings
8Strong Buy
7Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 2, 2026 | Wedbush | MAINTAIN | Outperform → Outperform |
| Jun 1, 2026 | BTIG | MAINTAIN | Buy → Buy |
| Jun 1, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| May 27, 2026 | BTIG | REITERATE | Buy → Buy |
| May 11, 2026 | Guggenheim | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.64 ▼ -31.7% | $-0.79 — $-0.60 | 25% YoY | 8 |
| Next Q | $-0.67 ▼ -29.9% | $-0.83 — $-0.61 | -39% YoY | 8 |
| Current FY | $-2.64 ▼ -21.2% | $-3.25 — $-2.45 | 17% YoY | 9 |
| Next FY | $-2.61 ▼ -23.7% | $-2.86 — $-2.30 | 1% YoY | 8 |
Latest Reports
BEARISH
Press
6/10
Jade Biosciences closed a public offering of 11.5M shares at $15.00/share, raising $172.5M in gross proceeds. The procee
Jun 5, 2026
BULLISH
8-K
7/10
Jade Biosciences reported interim Phase 1 data for JADE101, an anti-APRIL antibody for IgAN. The data showed ~70% mean I
Jun 5, 2026
BEARISH
8-K
6/10
Jade Biosciences priced a public offering of 10,000,000 shares of common stock at $15.00 per share, with an underwriter
Jun 4, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $99.6M | ADD |
| RA CAPITAL MANAGEMENT, L.P. | $51.6M | DOUBLED |
| JANUS HENDERSON GROUP PLC | $43.6M | NEW |
| BlackRock, Inc. | $32.5M | ADD |
| VANGUARD CAPITAL MANAGEMENT LLC | $25.2M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 9, 2026 | Fairmount Funds | A | $0.00 |
| Jun 9, 2026 | Lavelle Erin | A | $0.00 |
| Jun 9, 2026 | DOBMEIER ERIC | A | $0.00 |
| Jun 9, 2026 | Klein Lawrence | A | $0.00 |
| Jun 9, 2026 | CAIN CHRISTOPHER | A | $0.00 |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
50 institutional holders with $351.9M total value (25,076,485 shares) as of 2026-Q1. Top holders: FMR, RA, JANUS. Net selling activity: 12 institutions trimmed/exited vs 8 added.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 7,085,423 | $99.6M | 28.3% | ADD +41.0% |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 3,671,083 | $51.6M | 14.7% | DOUBLED +245.6% |
| 3 | JANUS HENDERSON GROUP PLC | 3,105,669 | $43.6M | 12.4% | NEW |
| 4 | BlackRock, Inc. | 2,313,949 | $32.5M | 9.2% | ADD +33.5% |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 1,796,652 | $25.2M | 7.2% | — |
| 6 | BAKER BROS. ADVISORS LP | 1,641,137 | $23.1M | 6.6% | NEW |
| 7 | MARSHALL WACE, LLP | 944,776 | $13.3M | 3.8% | DOUBLED +2198.5% |
| 8 | STATE STREET CORP | 655,690 | $9.2M | 2.6% | ADD +28.8% |
| 9 | DRIEHAUS CAPITAL MANAGEMENT LLC | 635,498 | $8.9M | 2.5% | TRIM -28.4% |
| 10 | RTW INVESTMENTS, LP | 573,205 | $8.1M | 2.3% | TRIM -60.4% |
| 11 | BALYASNY ASSET MANAGEMENT L.P. | 402,489 | $5.7M | 1.6% | — |
| 12 | Point72 Asset Management, L.P. | 264,315 | $3.7M | 1.1% | TRIM -52.7% |
| 13 | VANGUARD FIDUCIARY TRUST CO | 219,497 | $3.1M | 0.9% | — |
| 14 | VANGUARD PORTFOLIO MANAGEMENT LLC | 211,319 | $3.0M | 0.8% | — |
| 15 | Connor, Clark & Lunn Investment Management Ltd. | 169,051 | $2.4M | 0.7% | DOUBLED +151.5% |
| 16 | GOLDMAN SACHS GROUP INC | 153,037 | $2.2M | 0.6% | — |
| 17 | CITADEL ADVISORS LLC | 137,222 | $1.9M | 0.5% | — |
| 18 | RENAISSANCE TECHNOLOGIES LLC | 135,039 | $1.9M | 0.5% | ADD +94.0% |
| 19 | WELLINGTON MANAGEMENT GROUP LLP | 129,166 | $1.8M | 0.5% | ADD +25.9% |
| 20 | Russell Investments Group, Ltd. | 107,596 | $1.5M | 0.4% | DOUBLED +1713.8% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | NEW | — | 3,105,669 | — | $43.6M | 2026-Q1 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | TRIM | 887,179 | 635,498 | -28.4% | $8.9M | 2026-Q1 |
| RTW INVESTMENTS, LP | TRIM | 1,449,273 | 573,205 | -60.4% | $8.1M | 2026-Q1 |
| Point72 Asset Management, L.P. | TRIM | 558,474 | 264,315 | -52.7% | $3.7M | 2026-Q1 |
| Connor, Clark & Lunn Investment Management Ltd. | DOUBLED | 67,230 | 169,051 | +151.5% | $2.4M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 69,601 | 135,039 | +94.0% | $1.9M | 2026-Q1 |
| WELLINGTON MANAGEMENT GROUP LLP | ADD | 102,620 | 129,166 | +25.9% | $1.8M | 2026-Q1 |
| Russell Investments Group, Ltd. | DOUBLED | 5,932 | 107,596 | +1713.8% | $1.5M | 2026-Q1 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | TRIM | 125,772 | 91,647 | -27.1% | $1.3M | 2026-Q1 |
| MORGAN STANLEY | TRIM | 79,767 | 50,595 | -36.6% | $710.9K | 2026-Q1 |
| Nuveen, LLC | TRIM | 124,545 | 46,236 | -62.9% | $649.6K | 2026-Q1 |
| Invesco Ltd. | NEAR_EXIT | 199,727 | 29,560 | -85.2% | $415.3K | 2026-Q1 |
| MetLife Investment Management, LLC | TRIM | 26,069 | 17,935 | -31.2% | $252.0K | 2026-Q1 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | TRIM | 21,520 | 14,961 | -30.5% | $210.2K | 2026-Q1 |
| ExodusPoint Capital Management, LP | NEAR_EXIT | 287,587 | 14,131 | -95.1% | $198.5K | 2026-Q1 |
| Legal & General Group Plc | TRIM | 4,130 | 2,805 | -32.1% | $39.4K | 2026-Q1 |
| NISA INVESTMENT ADVISORS, LLC | DOUBLED | 471 | 1,371 | +191.1% | $19.3K | 2026-Q1 |
| Allworth Financial LP | DOUBLED | 24 | 100 | +316.7% | $1.4K | 2026-Q1 |
| CWM, LLC | ADD | 39 | 75 | +92.3% | $1.1K | 2026-Q1 |
| GROUP ONE TRADING LLC | NEAR_EXIT | 4,195 | 4 | -99.9% | $56.00 | 2026-Q1 |
| FMR LLC | ADD | 4,888,781 | 6,894,488 | +41.0% | $106.4M | 2025-Q4 |
| RA CAPITAL MANAGEMENT, L.P. | DOUBLED | 1,062,326 | 3,671,083 | +245.6% | $56.6M | 2025-Q4 |
| BlackRock, Inc. | ADD | 2,150,203 | 2,870,313 | +33.5% | $44.3M | 2025-Q4 |
| BAKER BROS. ADVISORS LP | NEW | — | 1,641,137 | — | $25.3M | 2025-Q4 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | TRIM | 1,255,798 | 887,179 | -29.4% | $13.7M | 2025-Q4 |
9 unique insiders with 13 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 9, 2026 | Fairmount Funds Management LLC | Director | AWARD | 34,843 | — | — |
| Jun 9, 2026 | Lavelle Erin | Director | AWARD | 34,843 | — | — |
| Jun 9, 2026 | DOBMEIER ERIC | Director | AWARD | 34,843 | — | — |
| Jun 9, 2026 | Klein Lawrence Otto | Director | AWARD | 34,843 | — | — |
| Jun 9, 2026 | CAIN CHRISTOPHER W. | Director | AWARD | 34,843 | — | — |
| Feb 12, 2026 | Dahms Bradford D. | Chief Financial Officer | AWARD | 37,813 | — | — |
| Feb 12, 2026 | Dahms Bradford D. | Chief Financial Officer | AWARD | 226,875 | — | — |
| Feb 12, 2026 | King Andrew James | See Remarks | AWARD | 41,250 | — | — |
| Feb 12, 2026 | King Andrew James | See Remarks | AWARD | 247,500 | — | — |
| Feb 12, 2026 | Balta Elizabeth | See Remarks | AWARD | 28,125 | — | — |
| Feb 12, 2026 | Balta Elizabeth | See Remarks | AWARD | 168,750 | — | — |
| Feb 12, 2026 | Frohlich Tom | Chief Executive Officer | AWARD | 78,750 | — | — |
| Feb 12, 2026 | Frohlich Tom | Chief Executive Officer | AWARD | 472,500 | — | — |
9 SEC filing reports analyzed. Sentiment: 1 bullish, 6 bearish, 0 mixed, 2 neutral. Avg impact: 6.0/10.
BULLISH
8-K
7/10
Jade Biosciences reported interim Phase 1 data for JADE101, an anti-APRIL antibody for IgAN. The dat
Jun 5, 2026
BEARISH
8-K
6/10
Jade Biosciences priced a public offering of 10,000,000 shares of common stock at $15.00 per share,
Jun 4, 2026
BEARISH
424B5
7/10
Jade Biosciences priced a $150M underwritten public offering of 10M shares at $15.00/share (14.7% di
Jun 4, 2026
BEARISH
424B5
6/10
Jade Biosciences filed a preliminary 424B5 prospectus supplement for an underwritten public offering
Jun 3, 2026
BEARISH
EFFECT
7/10
Two S-3 shelf registrations for Jade Biosciences became effective on May 15, 2026. File No. 333-2956
May 18, 2026
BEARISH
S-3
7/10
Jade Biosciences filed an S-3 resale registration for up to 39.5M shares held by selling stockholder
May 7, 2026
BEARISH
S-3
7/10
Jade Biosciences filed a $600M universal shelf registration statement, including a $200M at-the-mark
May 7, 2026
NEUTRAL
8-K
4/10
Jade Biosciences reported Q1 2026 EPS of -$0.57, missing consensus of -$0.52 by 9.6%. Net loss widen
May 7, 2026
NEUTRAL
8-K
3/10
Jade Biosciences appointed Andrew King, previously Chief Scientific Officer and Head of R&D, as Pres
Apr 22, 2026
BEARISH
6/10
Jade Biosciences closed a public offering of 11.5M shares at $15.00/share, raising $172.5M in gross
Jun 5, 2026
BEARISH
6/10
Jade Biosciences priced a public offering of 10 million shares at $15.00 per share, expecting gross
Jun 4, 2026
BEARISH
6/10
Jade Biosciences announced an underwritten public offering of common stock and pre-funded warrants,
Jun 3, 2026
NEUTRAL
3/10
Jade Biosciences announced the first participant has been dosed in a Phase 1 clinical trial of JADE2
May 26, 2026
MIXED
6/10
Jade Biosciences reported its full-year 2025 financial results, highlighting a strong cash position
Mar 6, 2026
Current analyst consensus: Strong Buy (94% buy). Based on 16 analysts: 8 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$49.00 mean target
+219.4% upside
Strong Buy (1.00)
$40.00 Low
$74.00 High
| Metric | Value |
|---|---|
| Current Price | $15.34 |
| Target Low | $40.00 |
| Target Mean | $49.00 |
| Target Median | $45.00 |
| Target High | $74.00 |
| # Analysts | 7 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.64 | $-0.79 | $-0.60 | 25.1% | -31.7% | 0↑ 8↓ | $0.0B | 0.0% | 8 |
| Next Q 2026-09-30 |
$-0.67 | $-0.83 | $-0.61 | -39.1% | -29.9% | 0↑ 8↓ | $0.0B | 0.0% | 8 |
| Current FY 2026-12-31 |
$-2.64 | $-3.25 | $-2.45 | 17.3% | -21.2% | 0↑ 7↓ | $0.0B | 0.0% | 9 |
| Next FY 2027-12-31 |
$-2.61 | $-2.86 | $-2.30 | 0.9% | -23.7% | 0↑ 8↓ | $0.0B | 0.0% | 8 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.644 | |
| 7d ago | $-0.621 | -0.022 |
| 30d ago | $-0.489 | -0.155 |
| 60d ago | $-0.489 | -0.155 |
| 90d ago | $-0.460 | -0.184 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 2, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Jun 1, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Jun 1, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 27, 2026 | BTIG | REITERATE | Buy | Buy |
| May 11, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| May 11, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Apr 27, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 25, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 16, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Mar 11, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Mar 9, 2026 | Wedbush | REITERATE | Outperform | Outperform |
| Jan 7, 2026 | HC Wainwright & Co. | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 8 | 7 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 8 | 7 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 8 | 7 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 7 | 6 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 7 | 6 | 1 | 0 | 0 | 93% | |
| Jan 1, 2026 | 7 | 5 | 1 | 0 | 0 | 92% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
2 mentions
0 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 15, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Apr 15, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
Jun 10, 2026
short_volume
Short Volume: JBIO — 62.5% short (0.4M / 0.7M)
Short: 413,618 | Exempt: 0 | TRF Vol: 661,824 | Short Ratio: 62.5% | Off-exchange volume (dark pool + OTC)
Jun 9, 2026
short_volume
Short Volume: JBIO — 60.8% short (0.4M / 0.7M)
Short: 446,242 | Exempt: 337 | TRF Vol: 733,979 | Short Ratio: 60.8% | Off-exchange volume (dark pool + OTC)
Jun 8, 2026
short_volume
Short Volume: JBIO — 60.9% short (0.3M / 0.5M)
Short: 312,663 | Exempt: 12,483 | TRF Vol: 513,077 | Short Ratio: 60.9% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
offering
Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
<p>SAN FRANCISCO and VANCOUVER, British Columbia, June 05, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO),
Jun 4, 2026
offering
Jade Biosciences Announces Pricing of Public Offering of Common Stock
<p align="left">SAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (N
Jun 3, 2026
offering
Jade Biosciences Announces Proposed Underwritten Public Offering
<p>SAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO),
Jun 1, 2026
fda
Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy
<p>SAN FRANCISCO and VANCOUVER, British Columbia, June 01, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO),
May 29, 2026
fda
Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy
<p>SAN FRANCISCO and VANCOUVER, British Columbia, May 29, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO),
May 26, 2026
fda
Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody
<p>SAN FRANCISCO and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO),
May 26, 2026
fda
Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy
<p>SAN FRANCISCO and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO),
May 7, 2026
earnings
Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
<p>SAN FRANCISCO and VANCOUVER, British Columbia, May 07, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO),
Apr 29, 2026
short_volume
Short Volume: JBIO — 66.2% short (0.4M / 0.7M)
Short: 438,659 | Exempt: 2,026 | TRF Vol: 662,243 | Short Ratio: 66.2% | Off-exchange volume (dark pool + OTC)
Apr 27, 2026
earnings_calendar
JBIO Q1 2026 Earnings Before Market Open — 2026-04-27
Apr 23, 2026
other
Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
<p align="left">SAN FRANCISCO and VANCOUVER, British Columbia, April 23, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (
Apr 21, 2026
short_volume
Short Volume: JBIO — 67.1% short (0.4M / 0.5M)
Short: 359,983 | Exempt: 0 | TRF Vol: 536,792 | Short Ratio: 67.1% | Off-exchange volume (dark pool + OTC)